Pharvaris N.V. (PHVS)

$PHVS Q4 '25 Earnings Results & Recap Pharvaris plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026 for the on-demand treatment of acute attacks of HAE.

$PHVS i think pharvaris has a good chance of success in upcoming ph3, but thoughts on investment upside at current market cap? @Night_Owl_Biotech --fdmc: $2.35B (at $30/sh) --cash: $300 million as of Dec 2025 --catalyst: 3Q 2026 topline data from the CHAPTER-3 pivotal Phase 3 study for the prophylactic treatment of HAE --combined pys estimates: $1-1.25B --predicted buyout on success: $3-4b

$PHVS just dropped a major update and the HAE story is getting real. The next catalyst is already in motion: U.S. NDA for deucrictibant IR targeting 1H 2026. That’s a potential on-demand treatment stepping closer to the finish line. Even bigger—enrollment is DONE for the pivotal XR prophylactic study, with topline data expected in 3Q 2026. That’s a huge de-risking milestone for the pipeline. Early data is also turning heads: symptom relief in just ~1.28 hours. If that holds up, this could be a meaningful improvement over current options. Meanwhile, the balance sheet remains solid with ~€292M cash, funding ongoing late-stage trials and continued pipeline expansion (CREAATE study still enrolling). Yes, they’re burning cash (~€176M FY loss), but that’s typical at this stage of aggressive clinical development. This is a pure pipeline-driven story—watch for data readouts. That’s where the real move will come from

$BCRX here’s what I think is going on.. A banker Likely leaked that there is a contingent offer on the table based on the results of the $PHVS data that is coming due any day now someone miss reported and leaked this and hence the stock has run up

RBC Capital reiterated $BCRX Outperform; $13, and said:::Recent unconfirmed media reports ( Betaville, 3/16 ) that BCRX could potentially be a takeout target have likely contributed to recent stock increase. Updating our prior takeout analysis, we believe that even with shares +24% YTD, shares remain undervalued across all takeout scenarios ($12-$20/share) and as an independent company (PT $13). While we acknowledge upcoming 3Q26 data from oral HAE prophy competitor $PHVS could have some impact on BCRX, our survey work and KOL feedback suggests that Orladeyo is likely to still have a meaningful role within the treatment paradigm even upon PHVS success, and could see a growing role for BCRX's next-gen agent navenibart as well among the longer-acting prophy injectables. We still see some upside potential from here; increasing downside floor and upside potential scenarios ($7/$20).

$PHVS RSI: 43.51, MACD: -0.1831 Vol: 0.90, MA20: 27.05, MA50: 26.72 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

$PHVS Pharvaris reports results from study of patient experience during HAE attacks Pharvaris announced that results from a Pharvaris-sponsored non-interventional, mixed methods, real-world study assessing the patient experience during acute HAE attacks across alternative endpoints used in clinical studies have been published in Clinical Reviews in Allergy & Immunology. The study evaluated the patient experience with HAE attack manifestations, and what constitutes meaningful changes in those manifestations, to support the inclusion of meaningful endpoints in clinical studies for on-demand treatment, or ODT, of HAE attacks, such as RAPIDe-3. Although approved medicines exist for the on-demand treatment of HAE attacks, there have been no head-to-head studies of on-demand therapies, and cross-trial comparisons have been challenging due to lack of uniformity in study design. Additionally, generation of evidence related to the key symptoms experienced by people during HAE attacks, insights into the subsequent perception from patients as to what are clinically-meaningful changes in symptoms, validation of the content of various patient-reported outcome, or PRO, instruments to support the evaluation of those symptoms, and confirmation of patient understanding and interpretation of that content, all could help in the evaluation of on-demand therapies by regulators, payers, and the HAE community. This mixed methods study provides strong evidence that the PGI and AMRA instruments are reliable, valid, and sensitive tools for assessing PROs in HAE attacks. Within the PRO assessments, most concepts were considered important by participants. Qualitative interviews confirmed that even relatively small improvements could be meaningful, such as the moment an attack was no longer worsening, as captured by the endpoint of End of Progression. Consistency across all PRO assessments of attack manifestation and response assessment were seen; End of Progression was the first-in-time achieved endpoint, followed by symptom relief, then symptom resolution. Importantly, the median time to onset of initial symptom relief as measured as PGI-C rating of at least "a little better" aligned more closely with the timing of AMRA-3 greater than or equal to20% than with the timing of AMRA-3 greater than or equal to30%. These results informed the hierarchy of endpoints in the Phase 3 RAPIDe-3 trial of deucrictibant and may also inform future trials of ODTs for HAE attacks.

$PHVS Current Stock Price: $26.66 Contracts to trade: $25.0 PHVS Mar 20 2026 Call Entry: $0.65 Exit: $1.09 ROI: 68% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

$PHVS RSI: 59.25, MACD: 0.4183 Vol: 0.80, MA20: 27.28, MA50: 26.61 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

#SHOWTIME American Academy of Allergy Asthma and Immunology Meeting (February 27 - March 1) Scheduled to appear: $COGT, $DBV, $ENTA, $PHVS, $SPRY